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Purpose—Implementation research provides a structure for evaluating the clinical integration of 
genomic medicine interventions. This paper describes the Implementing GeNomics In PracTicE 
(IGNITE) Network’s efforts to promote: 1) a broader understanding of genomic medicine 
implementation research; and 2) the sharing of knowledge generated in the network.
Methods—To facilitate this goal the IGNITE Network Common Measures Working Group 
(CMG) members adopted the Consolidated Framework for Implementation Research (CFIR) to 
guide their approach to: identifying constructs and measures relevant to evaluating genomic 
medicine as a whole, standardizing data collection across projects, and combining data in a 
centralized resource for cross network analyses.
Results—CMG identified ten high-priority CFIR constructs as important for genomic medicine. 
Of those, eight didn’t have standardized measurement instruments. Therefore, we developed four 
survey tools to address this gap. In addition, we identified seven high-priority constructs related to 
patients, families, and communities that did not map to CFIR constructs. Both sets of constructs 
were combined to create a draft genomic medicine implementation model.
Conclusion—We developed processes to identify constructs deemed valuable for genomic 
medicine implementation and codified them in a model. These resources are freely available to 
facilitate knowledge generation and sharing across the field.
Keywords
implementation; genomic medicine; common measures; consolidated framework; IGNITE
INTRODUCTION
In 2013, the National Human Genome Research Institute established the IGNITE 
(Implementing GeNomics In PracTicE) Network to support development, implementation, 
and dissemination of methods that incorporate genomic medicine information into clinical 
care.1 The Network includes six projects, affiliate members, coordinating center, and 
Working Groups to facilitate cross-network collaboration.1 Through the work of network 
members, IGNITE is poised to provide a substantial impact on genomic medicine in the 
‘real-world.’ “Its stated goals are to expand and link existing genomic medicine 
implementation efforts; develop new collaborative projects and methods for genomic 
medicine implementation in diverse settings and populations; contribute to the evidence base 
of outcomes following the use of genomic information for clinical care; and define, share 
and disseminate best-practices of genomic medicine implementation, diffusion and 
sustainability in diverse settings.”
While all six IGNITE projects are aligned through their work in genomic medicine, each 
differs in their intervention (i.e., pharmacogenomics, disease risk assessment, or disease 
diagnosis), and patient and provider populations. For specifics on each project’s study, refer 
to the IGNITE website (ignite-genomics.org). IGNITE’s diversity is, in large part, a direct 
reflection of the current state of affairs in genomic medicine: an explosion of research results 
that have not yet sufficiently infiltrated clinical practice to reach patients or providers, 
particularly those with the fewest resources and greatest challenges to achieving better 
health. IGNITE members are committed to understanding and addressing barriers to 
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dissemination of actionable genomics findings, and to understanding population impact, 
particularly among underrepresented populations. IGNITE is thus comprised of a substantial 
network of diverse clinicians, practice settings, patients, and investigators in geographically 
widespread areas with variable levels of exposure to genomics. As such, IGNITE affords a 
rich opportunity to explore, test, institutionalize, and disseminate programs to translate 
genomic medicine into routine practice. Together, IGNITE investigators, representing a wide 
array of genomic, clinical, stakeholder engagement, and technological expertise, are 
discovering best-practices for conducting research, building systems to make genomic 
information more accessible and actionable, and rigorously measuring their barriers, 
facilitators, and impact.2
The wealth of evidence being generated by each IGNITE project is beginning to lay the 
groundwork for understanding relevant issues around barriers to implementation, 
effectiveness, and stakeholder value. However, given the diversity of projects, common 
themes could be difficult to discern. To help facilitate identification of foundational evidence 
that could broadly guide implementation of genomic medicine, the network developed the 
Common Measures Working Group (CMG) (https://ignite-genomics.org/network/working-
groups-interest-groups/) at its inaugural meeting in June 2013. The mission of the working 
group is “to gather data, evaluate, and disseminate methods of genomic medicine 
implementation research across diverse projects conducted by IGNITE members.” To 
achieve this mission, the working group developed a plan to identify constructs and 
measures relevant to evaluating genomic medicine interventions as a whole, standardize 
data collection across projects, combine data in a centralized resource for cross network 
analyses, and develop a testable genomic medicine implementation research model based 
on the findings of IGNITE research. The database, containing data derived from the body 
of implementation research and standardized across contexts, is the type of queriable 
resource that could guide implementations in a learning healthcare system as described by 
Chambers, et al.3 In this way, the group felt it could balance the diversity, enhance external 
validity, and increase statistical power over what could be generated by each project alone. 
The objective of this paper is to describe the process the CMG is employing to meet its 
mission and the products of the work to date.
METHODS AND RESULTS
The CMG, comprised of 23 members (representing every project plus interested IGNITE 
affiliates) met twice monthly via Web-Ex. To achieve its goals, the CMG established a 
process for identifying common measures, defined steps to evaluate those measures, and 
reviewed existing literature for similar projects2 (Figure 1).
After reviewing the implementation research literature, the CMG selected the Consolidated 
Framework for Implementation Research (CFIR)4 (http://cfirguide.org/) to guide our 
approach, since the framework allowed us to: 1) think broadly about common measures, 
ensuring that it addressed the full spectrum of implementation characteristics; and 2) share 
knowledge generated by IGNITE with other genomic medicine projects and networks. CFIR 
is a framework developed to clearly described terminology and definitions for a 
comprehensive collection of constructs, drawn from published models (http://cfirguide.org/).
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5
 As such, it pulls together all existing implementation models into a comprehensive 
ontology of overarching themes (domains and constructs) that are postulated to be important 
in implementation. Unlike implementation models, it does not assume there is any specific 
relationship between individual constructs or constructs and outcomes. It simply lists them 
all in an organized (consolidated) format- thus its name “Consolidated Framework”. It 
comprises 39 constructs organized across five domains (Figure 2): 1) Innovation 
Characteristics; 2) Outer Setting; 3) Inner Setting; 4) Characteristics of Individuals; and 5) 
Process, which are hypothesized to interact in dynamic and complex ways. Thus the CFIR is 
an ideal mechanism for establishing a common structure to facilitate knowledge generation 
and sharing across the diverse settings, populations, and innovations that make up the 
IGNITE network projects.6,7
The methods and results below are organized according to the CMG’s goals outlined in the 
introduction: identify constructs and measures relevant to genomic medicine as a whole, 
standardize data collection across projects, combine data in a centralized resource for 
cross network analyses, and develop a testable genomic medicine implementation 
research model based on the findings of IGNITE research.
Identify Constructs and Measures Relevant To Genomic Medicine
The CMG followed three steps to identify and develop common measures that could 
facilitate genomic implementation research: (1) review CFIR constructs and prioritize them 
in order of perceived value for genomic medicine; (2) compile a list of all measures 
collected by each project and map them to CFIR constructs (if able); and (3) identify 
constructs relevant to genomic medicine that are not represented in CFIR. In this way, we 
would be able to assess two different but equally important aspects of the existing projects’ 
protocols: where projects were assessing similar constructs, and where constructs that were 
deemed valuable to the network were not being measured.
Step 1 (Methods)—each project team independently rated (in order of perceived value for 
genomic medicine) the 39 CFIR constructs across all five domains using a 3-point scale: 
3=very important, 2=somewhat important, 1=not important. Next, ratings for each of the 39 
constructs were summed and ranked in order of value (highest summed score to lowest). The 
ten highest ranked constructs, plus any constructs not in the top ten that had been rated as 
“very important” by at least one project, were identified as high-priority. These constructs 
were presented to the full working group and discussed to ensure consensus on the list of 
high priority CFIR constructs.
Step 1 (Results)—Initial rankings identified 16 CFIR constructs or sub-constructs 
supported by all projects trialability, adaptability, relative advantage, and cost (domain: 
INTERVENTION CHARACTERISTICS); patient needs and resources (domain: OUTER 
SETTING); organization’s structural characteristics, networks and communications, culture, 
implementation climate (relative priority), and readiness for implementation (leadership 
engagement, available resources, access to knowledge and information) (domain: INNER 
SETTING); knowledge and beliefs about the intervention, and self-efficacy (domain: 
INDIVIDUALS’ CHARACTERISTICS); and planning, engaging, executing, and reflecting 
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& evaluating (domain: PROCESS) as potential high-priority constructs for the network. Just 
as importantly, no projects supported intervention source, design quality & packaging, peer 
pressure, organizational incentives/rewards, other personal attributes, or external change 
agents as high- priority constructs. Table 1 shows the final results of the ranking procedure, 
identifying the ten highest ranking constructs, which were then used to frame data collection 
for the network.
Step 2 (Methods)—Each project listed all of the domains (and corresponding measures) 
that they planned to assess or were already assessing (depending upon how far along they 
were in initiating their study) within the patient, provider, and health system levels. For 
example, domains in the patient level included: demographics, quality of life, laboratory 
data, decisional processes, social influences, health literacy, attitudes, beliefs, knowledge, 
readiness to change, behavior, satisfaction, intention, genetic results, family history, and 
health outcomes. This classification aided in identifying projects that were measuring the 
same domains but with different instruments, facilitating discussions amongst projects as to 
whether a) projects not currently measuring a domain where others were, would want to 
include that domain in their assessments, and b) whether projects assessing the same domain 
with different measures would be willing to use a common instrument. Next, all measures 
were mapped to their corresponding CFIR construct. Mapping was initiated first by each 
project independently, and then by one of the CFIR developers (LJD). During this process, if 
a measure was consistently mapped to the same construct, it was automatically assigned to 
the construct; if there was disagreement, consensus was reached through discussions 
facilitated by Dr. Damschroder. Since, as is often the case, multiple measures were mapped 
to the same construct, measures within constructs were prioritized using the same process as 
that for the ranking constructs (step 1).
Step 2 (Results)—Table 1 lists the highest priority CFIR domains associated with each of 
the high priority constructs. Note that most of the measures initially planned for inclusion in 
study protocols did not assess high priority CFIR constructs and most of the high priority 
constructs did not have published measurement instruments.
Step 3—In many cases, measures in step 2 could not be mapped to a CFIR construct. Since 
existing evidence suggests that identifying and describing key contextual factors, even those 
that fall outside of established CFIR construct, is valuable because they can affect patient 
outcomes through their influence on implementation, we included these domains and 
associated measures as high priority constructs when they were considered critical for 
understanding genomic medicine. This determination was made in the same way that CFIR 
constructs were determined to be high priority (step 1). To do this, when measures could not 
be mapped to CFIR constructs, they were “mapped” to their underlying domain and the 
domain added as a construct to the list of high priority genomic medicine constructs (from 
step 1).
Step 3 (Results)—After comparing CFIR constructs to the projects’ compiled list of 
domains and measures, it became clear that CFIR lacks a well-defined representation of 
patient-related domains. The CFIR domain “Individual’s Characteristics” reflects individuals 
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within the organization and while patients are part of the health care organization and are 
essential to assessing intervention effectiveness, they are a less influential component of 
implementation success in healthcare settings than administrators and physicians. The 
working group therefore identified patient domains highly relevant to genomic medicine 
implementation and included these in Table 1 as non-CFIR high priority constructs.
The ultimate result was a matrix that consisted of CFIR and non-CFIR constructs prioritized 
for their value to the network with a list of associated measures (also ranked). The matrix 
provided a simple method for identifying which high-priority constructs the network was 
already measuring and which were not. When measures were listed under a high-priority 
construct, the highest ranking measure was adopted as the preferred measure. For high-
priority constructs with no corresponding measures, a literature search was undertaken to 
identify if existing instruments could be adapted to genomic medicine, and, if none was 
identified, then measures were developed. These processes are described in the next section.
Standardize Data Collection Across Projects
To maximize the potential value of cross-network analyses, the working group needed to 
standardize data collection across projects wherever possible. This process occurred as an 
extension of step 2 in the “Identify constructs and measures relevant to genomic medicine” 
process (above). Two synergistic approaches were employed to facilitate standardized data 
collection: The first was to promote adoption of a single measure for each domain being 
assessed by more than one project, and the second was to develop measures for high-priority 
CFIR and non-CFIR constructs if no published standardized measure existed.
Promote adoption of a single measure for each domain (Methods)—As 
described earlier, all projects listed the domains they were measuring across the spectrum of 
stakeholders: patients, providers, and health systems. During this process it became clear 
that, in several cases, two or more projects were planning on assessing a domain (such as 
patient quality of life) but were using different measures to do so. To promote adoption of a 
single measure for as many measures as possible, regardless of whether they fell into a high 
priority construct/domain, the working group encouraged discussion amongst the projects by 
specifically calling attention to those domains and enabling project leadership to discuss 
them on a case by case basis.
Promote adoption of a single measure for each domain (Results)—During this 
process, common measures for several different domains were adopted by projects 
measuring them. Specifically, the network adopted the following measures: a single item 
from the SF-128 for self-related health, Voils’ survey for patient medication adherence9, a 
single item for patient health literacy10, the Patient Activation Measure11, and the 
Organizational Readiness for Implementation Change12. In addition, two projects initially 
planning on only assessing patient measures through the electronic medical record modified 
their protocol to incorporate patient/provider surveys using common measures identified 
here and below to enhance the feasibility of cross network analyses.
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Develop measures for high priority CFIR and non-CFIR constructs (Methods)
—As described in the “Identify Constructs and Measures Relevant To Genomic Medicine” 
process, Table 1 represents high priority CFIR and non-CFIR constructs important for 
genomic medicine. Importantly this process identified constructs as valuable that no project 
had previously considered measuring. To facilitate measurement, the CMG conducted 
literature reviews. When measures were identified, they were described and coded for 
standardized data collection across projects; when measures could not be identified, the 
working group developed measures with the help of a psychometrician.
Develop measures for high priority CFIR and non-CFIR constructs (Results)—
Four surveys were standardized and coded for use across the projects planning to survey 
patients and/or providers; all are available for download from the IGNITE SPARK toolbox 
(https://ignite-genomics.org/spark-toolbox/). The first survey agreed on and coded patient 
demographic and education measurement using the NIH-preferred measures. The second is 
a post-intervention patient survey that incorporates measures for patient attitudes towards a 
specific genomic intervention, intentions for sharing intervention results, and preferences for 
return of results. The third codifies provider’s demographics and practice/setting 
characteristics, including age, gender, race, ethnicity, practice setting, profession, specialty, 
and years in practice. The fourth is a provider survey designed as a pre-implementation 
survey that could also be employed post-intervention as well. This survey, initially 14 items 
which were then refined to 10, was developed by the CMG to address high-priority CFIR 
constructs (Table 1) including implementation climate, readiness for implementation, 
knowledge about the intervention, self-efficacy, and relative advantage.
Lastly, to promote the cross-network analysis, we categorized study interventions (i.e., as 
pharmacogenomic, disease risk assessment, or diagnostic) and identified several cross-study 
outcomes that could be assessed despite the disparate interventions. These included uptake 
of the genomic intervention by providers, frequency provider’s act on intervention 
recommendations, success of intervention on each study’s primary patient endpoint, pre-post 
change in patient’s diet and/or exercise habits, frequency that intervention results are 
actionable, and impact on mortality, disease incidence, hospitalizations, or ER visits.
Combine Data In A Centralized Resource For Cross Network Analyses
Methods—Common data were stored in a relational database (details provided in online 
supplement). To demonstrate the potential value of such a database, we performed a 
preliminary analysis using R software on patient-level data deposited in the resource 
database prior to August 12, 2016. Patient demographic features and responses to the patient 
survey were summarized within and across the IGNITE projects using summary statistics. 
Differences across projects were evaluated using chi-squared tests for project/intervention, 
sex, race, ethnicity, and education, and ANOVA F-test for age.
Results—Of the six projects, one was not collecting individual patient data and therefore 
was not able contribute to the patient data analysis. Of the remaining five projects, one was 
collecting data on paper and was not able to provide an electronic version by the time of 
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manuscript completion, and another opted not to implement the demographic or patient 
survey. Therefore, the patient analysis represents data contributed from three projects.
Across these three projects, there were 2430 patients (Table 2). All demographic features 
were reported by two projects, while one project reported all demographic features except 
for education level. Overall, the demographic features had high response rates: age and sex 
were reported for nearly all patients (99.5% for both age and sex), while ethnicity, race, and 
education response rates were slightly lower (77.0%, 90.0%, and 89.9% respectively). We 
note that nearly all demographic features, except sex, differ by project (age/race/education p-
values<1.0×10−5, ethnicity p-value=0.002). Patient responses to the pre-implementation 
common measures questions were less complete than the demographics responses. Four of 
the seven common measures questions had responses submitted by at least one project, and 
no single question had responses from all three projects. Three questions had responses from 
two different projects, and one question had response from only one project. The variability 
in number of projects reporting any given question resulted in patient response rates ranging 
from 9.87% to 73.4% of the 2340 patients with demographic information.
Develop a testable genomic medicine implementation research model based on the 
findings of IGNITE research
Methods—By following the steps outlined above, the working group gathered an 
abundance of data that, once organized, were able to inform a structural understanding of 
genomic medicine research implementation. We therefore leveraged these data to develop an 
IGNITE Genomic Medicine Implementation research conceptual model derived from 
published high-level models and informed by findings across the six IGNITE projects. The 
goal of the model is to serve as a resource for researchers, such that new evidence can 
inform and refine the model over time. The initial model was developed based upon high-
priority constructs, both within and outside of CFIR. Strategies used by the team to 
implement genomic medicine interventions were conceptualized as mechanisms of action 
aimed at effective implementation but that would be moderated (positively or negatively) by 
high-priority constructs at the organization, physician, and patient levels. More effective 
implementations of genomic medicine interventions were hypothesized to lead to better 
clinical or process outcomes.
Results—Based on high-priority constructs identified by the project teams, moderators that 
are hypothesized to influence implementation effectiveness were defined across four 
domains: 1) intervention characteristics; 2) characteristics of the organization’s inner setting; 
3) characteristics of clinicians involved with delivering the genomic medicine intervention; 
and 4) characteristics of the process of implementation. Therefore, the model flow suggests 
measuring those domains prior to implementation so they can inform the selection of the 
optimal implementation strategy. Figure 3 displays how the domains relate to each other and 
the implementation strategy; but specific constructs are not listed in the figure as they may 
differ in other implementation projects (e.g. assessing experience with return of results 
rather than intention to share results). For IGNITE they are reported in Table 1.
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DISCUSSION
The IGNITE Network’s Common Measures Working Group brought together six disparate 
projects to synthesize a model for understanding the process of genomic medicine 
implementation into clinical practice and to identify/develop standardized measures that may 
help to inform a broader understanding of genomic medicine implementation research. The 
key steps taken by the group to advance understanding beyond each individual project are 
formalized in this paper: 1) to outline a pathway for other networks who are interested in 
using a similar methodology; and 2) to provide tools for individual institutions/projects 
interested in genomic medicine implementation research. The model (Figure 3), developed 
with input from providers with diverse clinical settings, environments, and populations, is a 
simplified linear depiction of our complex nonlinear efforts that can is “testable” in that it is 
meant to be refined as results from ongoing work inform our understanding of this fast 
moving field. For example, if other implementation projects identify different or additional 
high priority constructs those should be added to list of options for that domain or if 
researchers find that in order to be successful all genomic implementation processes should 
include specific characteristics that are un-related to the constructs then the model should be 
updated to represent those findings.
One key finding of our work is that while the CFIR provides an excellent foundation upon 
which to conceptualize implementation and as a framework provides representation of 
constructs from across the entire field of implementation science, it does not fully capture all 
domains pertinent to genomic medicine. To address this, we expanded beyond the CFIR to 
incorporate domains relevant to patients, families, and local communities as CFIR (and thus 
the implementation models upon which it derived its list of constructs) is more specifically 
focused on factors relevant to the health system rather than local community values. In 
genomic medicine, the patient and the local culture around the patient are extremely 
important, with a large body of work devoted to understanding patient perceptions, anxiety, 
and personal utility. While these are not unique to genomic medicine, they have special 
emphasis when interventions address topics related to genomics- particularly for patients 
who are generally healthy and not pursuing a diagnostic odyssey.
Another key finding, that most projects were not initially measuring any of the CFIR 
constructs they had identified as high-priority, is an essential insight into genomic 
medicine’s current perceptions of implementation and forays into the field of 
implementation science. This work may help to guide other implementation projects to 
consider a broader conceptual view of implementation and which constructs could be 
valuable for them to address when selecting measures and outcomes. It is important to 
address these issues early prior to projects developing protocols to improve the ability to 
synergize data collection and methods. Five projects changed their protocols to incorporate 
relevant measures: two to incorporate patient surveys and three to adopt high priority 
measures (the “common measure”) for constructs that they were initially planning to 
measure, but with different measurement instruments. This shows the value of the measures 
developed; however, we were still limited in the data we were able to capture given that most 
projects had already begun when the CMG completed its evaluations.
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By thoroughly addressing these questions early in the network formation, we were able to 
enhance the scientific rigor of the network as a whole and facilitate cross study analyses that 
can address a wide variety of questions around implementation and effectiveness such as: (1) 
provider demographics, attributes and attitudes that predict uptake of genomic medicine; (2) 
the extent to which patients plan to and actually share their genetic information with 
relatives, friends and others; (3) patient attitudes toward genetic testing and its potential 
benefits and risks as perceived by those undergoing a variety of interventions; (4) influence 
of the genomic intervention and type of genomic intervention on health, well-being and self-
care/preventive behaviors by patients and provider practices. It is important to note that, 
while the diversity of the projects is desirable and leads to greater generalizability of cross-
network findings, it is also a challenge for combining data. Therefore, a number of questions 
cannot be answered by analyzing data from across the network; many can only be analyzed 
within each project. Yet, whenever possible, combining data across the network will provide 
unique insight into the field as a whole. We have defined cross-network measures as those 
that are being collected from three or more projects. To demonstrate the potential for these 
analyses, we reported a preliminary analysis of patient demographics and responses to the 
CMG developed patient survey (Table 2). These results are not meant to be taken as 
definitive “findings,” but, rather, as an example of what these data might look like.
The results of the Common Measures Working group’s efforts, which include the 
implementation model, surveys, and listing of high priority constructs, are available in the 
IGNITE Network’s “Supporting Practice through Application, Resources and Knowledge” 
(SPARK) toolbox (https://ignite-genomics.org/spark-toolbox/). SPARK provides free access 
to the products of our work, which may be useful to clinicians, patients, and educators, as 
well as researchers. It contains resources to educate and inform providers and patients as 
well as recommended measures to assess implementation effectiveness. The implementation 
research model is unique in that it is specifically tailored to genomics, a rapidly growing but 
still relatively underutilized tool within healthcare.
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Figure 1. 
Common Measures Working Group Process Plan for Developing Common Measures
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Figure 2. The Consolidated Framework for Implementation Research
Bolded constructs are those identified as high priority by IGNITE.
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Figure 3. 
Genomic Medicine Implementation Model Developed as part of the IGNITE Network
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Table 1
Shows those constructs identified as high priority and associated measures
CFIR Domain High Priority CFIR Construct Identified Measure
Outer setting No high priority constructs Not assessed
Inner Setting Implementation climate Readiness for 
implementation
Organizational Readiness for Implementation Change 
survey12
none
Individuals’ Characteristics Knowledge and beliefs about the intervention Qualitative interviews
Self-efficacy none
Intervention Characteristics Relative Advantage none
Cost Electronic Medical Record Data on utilization
Process Engaging none
Executing none
Reflecting and evaluating Qualitative interviews
Non-CFIR Domain Non-CFIR Construct Measure
Patients’ Characteristics Demographics NIH standard definition for demographics
Self-reported Health Single item from SF-12
Healthcare Activation PAM11
Medication Adherence Voils Medication Adherence survey9
Social Determinants Health Literacy Question10
Family and Community Various depending upon aspect measuring
Information Sharing Intention to share
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Table 2
Patient demographics and Patient baseline survey analysis from common measures database
Projects 
Contributing 
Data (N)
Patients 
Completing 
survey% (N)
Response Summary Level – 
percent/Mean (sd)
Demographic features 
by which responses vary 
Feature (p-value)*
Demographic Feature
Age 3 99.5% (2419) 56.84 (14.0) Project (< 0.00001)
Sex 3 99.6% (2420) Male – 32.3%
Female – 67.8%
none
Ethnicity 3 77.0% (1871) Non-Hispanic - 97.1%
Hispanic – 2.8%
Prefer not to Answer- 0.1%
Project (0.002)
Race 3 90.7% (2203) American Indian/Native Alaskan – 
0.4%
Asian – 1.0%
Black/African American – 14.4%
Native Hawaiian/Pacific Islander – 
0.2%
White – 81.8%
More than one Race – 2.1%
Prefer not to Answer – 0.1%
Project (< 0.00001)
Education Level 2 89.8% (2183) High school (12 years) or less – 
13.7%
Some college – 19.0%
College graduate – 27.5%
Postgraduate – 39.8%
Project (< 0.00001)
Patient pre-implementation 
survey items
“Is it a good idea to ___[e.g. get 
genetic testing] to find out 
whether ___[e.g. at risk for 
getting a disease]”
2 24.1% (586) Strongly disagree - 0.34%
Disagree – 0.34%
Neither agree nor disagree – 7.34%
Agree – 52.73%
Strongly Agree – 39.25%
Project (< 0.00001); age 
(0.000017)
“Do you plan to share [test] 
results with any one?”
2 24.6% (597) No – 19.3%
Yes – Family – 69.7%
Yes – Friends - 19.3%
Yes – Health Professional – 33.3%
Yes – Other – 1.0%
Unsure – 6.0%
Project (< 0.00001 – 
0.00145); age (0.00010 – 
0.045); sex (0.0028); race 
(0.00051 −0.025)**
“How confident are you filling 
out medical forms by yourself?”
2 73.4% (1783) Extremely – 78.74%
Quite a bit – 13.29%
Somewhat – 5.33%
A little bit– 1.74%
Not at all – 0.90%
Project (< 0.00001); age 
(0.002); ethnicity (0.03); 
race (< 0.00001); 
education level (< 
0.00001)
“How confident are you that you 
could get health-related advice or 
information if you needed it?”
1 240 (9.9%) Completely confident – 57.1%
Very confident – 23.8%
Somewhat confident – 16.2%
A little confident – 1.7%
Not confident at all – 1.2%
none
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